Cornerstone receives US court approval to acquire Factive
This article was originally published in Scrip
Executive Summary
Cornerstone Therapeutics has received approval from a US bankruptcy court to acquire certain commercial rights to the antibiotic Factive (gemifloxacin mesylate) from Oscient Pharmaceuticals, which filed for bankruptcy protection in July.